Edition:
United States

Progenics Pharmaceuticals Inc (PGNX.OQ)

PGNX.OQ on NASDAQ Stock Exchange Global Select Market

6.27USD
19 Jan 2018
Change (% chg)

$0.17 (+2.79%)
Prev Close
$6.10
Open
$6.10
Day's High
$6.30
Day's Low
$6.08
Volume
276,203
Avg. Vol
249,147
52-wk High
$11.71
52-wk Low
$4.61

Select another date:

Tue, Jan 2 2018

BRIEF-Progenics Pharmaceuticals Completes Enrollment In Phase 3 Study Of Psma-Targeted Imaging Agent 1404

* PROGENICS PHARMACEUTICALS COMPLETES ENROLLMENT IN PHASE 3 STUDY OF PSMA-TARGETED IMAGING AGENT 1404 Source text for Eikon: Further company coverage:

BRIEF-Progenics Pharmaceuticals Announces FDA Acceptance Of Marketing Application For Azedra In Pheochromocytoma And Paraganglioma

* PROGENICS PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR AZEDRA® (IOBENGUANE I 131) IN PHEOCHROMOCYTOMA AND PARAGANGLIOMA

BRIEF-Progenics Pharmaceuticals Q3 loss per share $0.22

* Progenics Pharmaceuticals announces third quarter 2017 financial results and business update

BRIEF-Progenics Pharmaceuticals provides update on timing of NDA submission for Azedra

* Progenics Pharmaceuticals provides update on timing of NDA submission for Azedra

BRIEF-Progenics Pharmaceuticals Q2 loss per share $0.24

* Progenics Pharmaceuticals announces second quarter 2017 financial results and business update

Select another date: